Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit
- PMID: 4050977
- PMCID: PMC1888024
Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit
Abstract
Acetyl glyceryl ether phosphorylcholine (AGEPC; 1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) was infused intravenously into rabbits (0.5 micrograms/kg); subsequently, temporal pulmonary alterations were assessed histologically. Within 30 seconds after AGEPC infusion, widespread platelet and neutrophil aggregates were distributed throughout the pulmonary microvasculature. Concomitantly, small muscular arteries and bronchioles throughout the lungs were contracted. Five minutes after AGEPC infusion, intravascular pulmonary platelet aggregates were less frequent and smaller than those observed at 30 seconds after infusion; however, AGEPC-induced pulmonary neutrophil sequestration persisted. Moreover, at this time, large mononucleated cells and damaged endothelial cells were prevalent throughout the pulmonary microvasculature. Sixty minutes after infusion, neither platelet aggregates nor arterial or bronchiolar constriction was observed. However, in most animals, neutrophils and large mononucleated cells were still abundant, and focal endothelial cell alterations persisted. In addition, discrete areas of interstitial hemorrhage around small and medium-sized arteries were present. These studies suggest that the intravascular release of AGEPC could initiate significant pulmonary injury and therefore could be an important etiologic factor in the development of inflammatory lung diseases.
Similar articles
-
Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.J Clin Invest. 1983 Feb;71(2):351-7. doi: 10.1172/jci110776. J Clin Invest. 1983. PMID: 6822668 Free PMC article.
-
Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon.Lab Invest. 1981 Oct;45(4):303-7. Lab Invest. 1981. PMID: 7300244
-
Ontogeny of the responsiveness to intravenous platelet-activating factor.Lab Invest. 1987 Sep;57(3):321-8. Lab Invest. 1987. PMID: 3626521
-
Intravascular pathobiology of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF). I. Intravenous infusion in guinea pigs.Immunol Lett. 1981 Aug;3(3):133-5. Immunol Lett. 1981. PMID: 7287060
-
AGEPC, a vasodilator phospholipid with profound circulatory actions.Prog Clin Biol Res. 1986;219:133-56. Prog Clin Biol Res. 1986. PMID: 3538024 Review.
Cited by
-
Lung injury mediated by antibodies to endothelium. II. Study of the effect of repeated antigen-antibody interactions in rabbits tolerant to heterologous antibody.Am J Pathol. 1987 May;127(2):216-28. Am J Pathol. 1987. PMID: 3034065 Free PMC article.
-
Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung.Br J Pharmacol. 1991 Sep;104(1):251-7. doi: 10.1111/j.1476-5381.1991.tb12415.x. Br J Pharmacol. 1991. PMID: 1786514 Free PMC article.
-
Platelet activating factor induced respiratory mucosal damage.Lipids. 1991 Dec;26(12):1287-91. doi: 10.1007/BF02536550. Lipids. 1991. PMID: 1819718
-
Provocation of pulmonary vascular endothelial injury in rabbits by human recombinant interleukin-1 beta.Infect Immun. 1988 Sep;56(9):2255-63. doi: 10.1128/iai.56.9.2255-2263.1988. Infect Immun. 1988. PMID: 3261716 Free PMC article.
-
Effects of platelet-activating factor on vascular permeability and granulocyte recruitment in the rat trachea.Lung. 1991;169(2):109-19. doi: 10.1007/BF02714148. Lung. 1991. PMID: 1648156
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources